Capillary leak syndrome future or investigational therapies
|
Capillary leak syndrome Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Capillary leak syndrome future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Capillary leak syndrome future or investigational therapies |
|
FDA on Capillary leak syndrome future or investigational therapies |
|
CDC on Capillary leak syndrome future or investigational therapies |
|
Capillary leak syndrome future or investigational therapies in the news |
|
Blogs on Capillary leak syndrome future or investigational therapies |
|
Risk calculators and risk factors for Capillary leak syndrome future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [[1]]; Associate Editor(s)-In-Chief: M. Hassan, M.B.B.S
Overview
The relationship between Capillary leak syndrome and post-episodic levels of monoclonal IgG are of interest and continue to be studied. In one out of five patients, a monoclonal IgG gammopathy has been found.
Future or Investigational therapies
After an attack, various substances were measured in the body including products derived the coagulation pathway, complement pathway, bradykinin generation, prostaglandins and histamine metabolism. Although these products were all in within normal limits, affected individuals were continuously found to have a monoclonal IgG gammopathy. Studies continue to be done to understand the relationship between monoclonal IgG gammopathy and Capillary leak syndrome.[1]
References
- ↑ Atkinson JP, Waldmann TA, Stein SF, Gelfand JA, Macdonald WJ, Heck LW; et al. (1977). "Systemic capillary leak syndrome and monoclonal IgG gammopathy; studies in a sixth patient and a review of the literature". Medicine (Baltimore). 56 (3): 225–39. doi:10.1097/00005792-197705000-00004. PMID 870792.